Iloprost Rafarm (Iloprost)

Iloprost is a synthetic analogue of prostacyclin (PGI2). It binds to prostacyclin (IP) receptors on pulmonary arterial smooth‑muscle cells, stimulating adenylate cyclase and raising cyclic AMP levels. This cascade produces vasodilation of the pulmonary vessels and inhibits platelet aggregation, reducing pulmonary arterial pressure.

The dosing regimen for Iloprost Rafarm is individualized and must be determined by a qualified prescriber. The healthcare professional will consider the patient’s clinical status, response to therapy, and any concomitant medications before setting the appropriate inhalation schedule.

Safety data for Iloprost during pregnancy and lactation are limited. Because potential risks to the fetus or infant cannot be ruled out, the drug should be used only if the potential benefit justifies the potential risk, and it is generally avoided unless absolutely necessary.

To place an order, submit an enquiry on the Iloprost Rafarm product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and import documentation.

Iloprost belongs to the prostacyclin analog class, offering inhaled delivery that targets the lungs directly and may cause fewer systemic side effects than intravenous prostacyclins. Compared with oral agents such as endothelin receptor antagonists, Iloprost provides rapid vasodilation but requires multiple daily inhalations, making adherence a key consideration.

Iloprost Rafarm should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture and direct sunlight. Do not freeze the solution, and keep the container tightly closed when not in use to maintain stability.

Iloprost Rafarm is administered by inhalation using a certified nebulizer device. The prescribed number of inhalations is typically performed several times per day, with each session lasting a few minutes. Patients should follow the device manufacturer’s instructions and the prescriber’s dosing schedule.

The most serious adverse reactions include significant hypotension, pulmonary edema, severe bronchospasm, bleeding due to platelet inhibition, and cardiac arrhythmias. Patients should be monitored for sudden drops in blood pressure, difficulty breathing, coughing up blood, or any irregular heart rhythms, and seek medical attention promptly if these occur.

Iloprost is contraindicated in patients with recent hemoptysis, active severe bronchospasm or uncontrolled asthma, and those who are hypersensitive to iloprost or any excipients in the formulation. Caution is also advised for patients with severe hepatic impairment or uncontrolled hypotension.